Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$0.3.

  • Tarsus Pharmaceuticals' EPS (Basic) rose 5081.97% to -$0.3 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.01, marking a year-over-year increase of 4668.44%. This contributed to the annual value of -$3.07 for FY2024, which is 3348.76% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' EPS (Basic) stood at -$0.3, which was up 5081.97% from -$0.48 recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year EPS (Basic) high stood at $0.31 for Q2 2021, and its period low was -$1.28 during Q3 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.7 (2021), whereas its average is -$0.7.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 12520.33% in 2021, then plummeted by 38750.0% in 2023.
  • Tarsus Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.7 in 2021, then surged by 30.49% to -$0.49 in 2022, then crashed by 159.18% to -$1.27 in 2023, then soared by 51.66% to -$0.61 in 2024, then soared by 51.13% to -$0.3 in 2025.
  • Its EPS (Basic) was -$0.3 in Q3 2025, compared to -$0.48 in Q2 2025 and -$0.64 in Q1 2025.